fda warning bpc 157 peptide products New Details 157 The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide Best BPC 157 Oral Supplements: ProHealth's Triple Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026 FDA May Reverse Ban on 14 PeptidesWhat It Means for Your Beauty Routine Allure